Bortezomib will raise the amount or impact of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Increased flibanserin adverse outcomes may come about if coadministered with several weak CYP3A4 inhibitors. B: Could be satisfactory. Either animal scientific studies demonstrate no hazard but human studies not accessible or animal reports https://creightonh554uoz0.glifeblog.com/profile